Kiora Pharmaceuticals received IND approval for Phase 2 study of KIO-101

On February 7, 2023, Kiora Pharmaceuticals issued a press release announcing that it has received investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of the Ocular Presentation of Rheumatoid Arthritis or other autoimmune diseases, or OPRA+. This study will enroll approximately 120 patients in a multi-center, controlled, randomized, double-masked trial assessing the safety and efficacy of KIO-101 eye drops in patients living with autoimmune disease who have signs and symptoms of ocular surface disease. The study is expected to begin enrolling patients in Australia in the first half of 2023.